Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Rating) have been given a consensus rating of "Buy" by the eleven analysts that are covering the stock, Marketbeat Ratings reports. Ten analysts have rated the stock with a buy rating. The average 1 year target price among brokerages that have covered the stock in the last year is $24.20.
Several research firms recently issued reports on TSHA. The Goldman Sachs Group lowered their price objective on Taysha Gene Therapies from $27.00 to $16.00 and set a "buy" rating on the stock in a report on Tuesday, May 24th. Needham & Company LLC lowered their price objective on Taysha Gene Therapies to $20.00 and set a "buy" rating on the stock in a report on Tuesday, May 17th. Wedbush lowered their price objective on Taysha Gene Therapies from $9.00 to $5.00 and set an "outperform" rating on the stock in a report on Friday, August 12th. Guggenheim lowered their price objective on Taysha Gene Therapies to $22.00 and set a "na" rating on the stock in a report on Tuesday, May 17th. Finally, Chardan Capital lowered their price objective on Taysha Gene Therapies from $34.00 to $32.00 and set a "buy" rating on the stock in a report on Friday, August 12th.
Get Taysha Gene Therapies alerts:Taysha Gene Therapies Price Performance
NASDAQ:TSHA opened at $3.16 on Monday. Taysha Gene Therapies has a 52 week low of $2.33 and a 52 week high of $21.90. The company has a quick ratio of 1.79, a current ratio of 1.79 and a debt-to-equity ratio of 1.15. The stock has a market capitalization of $129.85 million, a PE ratio of -0.66 and a beta of 0.99. The stock's 50-day moving average price is $4.06 and its 200-day moving average price is $4.56.
Insiders Place Their Bets
In other news, CFO Kamran Alam sold 7,476 shares of Taysha Gene Therapies stock in a transaction that occurred on Thursday, August 18th. The shares were sold at an average price of $3.87, for a total transaction of $28,932.12. Following the sale, the chief financial officer now owns 290,645 shares of the company's stock, valued at approximately $1,124,796.15. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CMO Suyash Prasad sold 23,923 shares of Taysha Gene Therapies stock in a transaction that occurred on Friday, July 1st. The shares were sold at an average price of $3.53, for a total transaction of $84,448.19. Following the sale, the chief marketing officer now owns 543,450 shares of the company's stock, valued at approximately $1,918,378.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Kamran Alam sold 7,476 shares of Taysha Gene Therapies stock in a transaction that occurred on Thursday, August 18th. The shares were sold at an average price of $3.87, for a total transaction of $28,932.12. Following the completion of the sale, the chief financial officer now owns 290,645 shares of the company's stock, valued at approximately $1,124,796.15. The disclosure for this sale can be found here. Insiders have sold 57,345 shares of company stock valued at $208,051 in the last ninety days. 42.40% of the stock is currently owned by corporate insiders.Institutional Trading of Taysha Gene Therapies
Several institutional investors have recently added to or reduced their stakes in TSHA. Northern Trust Corp increased its holdings in Taysha Gene Therapies by 1.4% in the 4th quarter. Northern Trust Corp now owns 214,970 shares of the company's stock valued at $2,504,000 after purchasing an additional 3,042 shares during the last quarter. ProShare Advisors LLC acquired a new stake in Taysha Gene Therapies in the 4th quarter valued at approximately $121,000. GSA Capital Partners LLP acquired a new stake in Taysha Gene Therapies in the 4th quarter valued at approximately $476,000. Virtus ETF Advisers LLC increased its holdings in Taysha Gene Therapies by 39.3% in the 4th quarter. Virtus ETF Advisers LLC now owns 11,519 shares of the company's stock valued at $134,000 after purchasing an additional 3,251 shares during the last quarter. Finally, 683 Capital Management LLC acquired a new stake in Taysha Gene Therapies in the 4th quarter valued at approximately $117,000. Institutional investors and hedge funds own 34.28% of the company's stock.
Taysha Gene Therapies Company Profile
(Get Rating)
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.
Featured Articles
- Get a free copy of the StockNews.com research report on Taysha Gene Therapies (TSHA)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.